Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 6,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patient Level Clear all
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Eco-anxiety Using Selfies

NCT05372705
View directory record Official record
Conditions
Ecology, Anxiety
Interventions
Short videos
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 18 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Phase 2 Interventional

Impact of Literacy Level on Patient Education and Health Among People With Arthritis

NCT00023205
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Polyarthritis
Interventions
11th grade reading level arthritis materials, Interactive in-person arthritis education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 28, 2026, 9:36 AM EDT
Terminated Phase 1Phase 2 Interventional

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

NCT04849910
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
VOR33, Mylotarg
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
La Jolla, California • Stanford, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 28, 2026, 9:36 AM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

NCT04713046
View directory record Official record
Conditions
HPV 16+ Recurrent or Metastatic Cancer
Interventions
CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

NCT00538642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 28, 2026, 9:36 AM EDT
Terminated Phase 1 Interventional

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

NCT00325741
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Hematopoietic Cell Transplantation
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 28, 2026, 9:36 AM EDT
Recruiting Not applicable Interventional

Hearing Aids for Veterans With Functional Hearing Difficulties

NCT06117254
View directory record Official record
Conditions
Auditory Processing Disorder
Interventions
Communication Counseling, Hearing Aids, Remote Microphones
Behavioral · Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 79 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

NCT03597594
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine, Thiotepa, CliniMACS, Donor Lymphocyte Infusion
Drug · Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Completed No phase listed Observational

Predicting the Development of Myocardial Depression in Acute Neurological Patients

NCT03801694
View directory record Official record
Conditions
Myocardial Depression, Takotsubo Syndrome, Subarachnoid Hemorrhage, Acute Ischemic Stroke
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Siliphos in Advanced Hepatocellular Carcinoma

NCT01129570
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Silybin
Drug
Lead sponsor
Abby Siegel
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 28, 2026, 9:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773
View directory record Official record
Conditions
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
Interventions
MGD024
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Manipulation of the Cervical Spine on Pain Biomarkers

NCT03176654
View directory record Official record
Conditions
Neck Pain, Posterior
Interventions
HVLAT manipulation, Sham HVLAT manipulation
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

Virtual Reality Therapy for Chronic Low Back Pain

NCT04409353
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Distraction-Based VR, Sham VR, Skills-Based VR, Activity Tracker
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 28, 2026, 9:36 AM EDT
Recruiting Phase 1 Interventional

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

NCT04775745
View directory record Official record
Conditions
CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Interventions
LP-168
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan

NCT00683020
View directory record Official record
Conditions
Diabetes
Interventions
ATSM Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Phase 1Phase 2 Interventional

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

NCT02705196
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel, atezolizumab
Genetic · Drug · Biological
Lead sponsor
Lokon Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Terminated Phase 1 Interventional

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas

NCT00716469
View directory record Official record
Conditions
Neurofibroma
Interventions
LS11
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 28, 2026, 9:36 AM EDT
Terminated Phase 1 Interventional

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

NCT04049383
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia
Interventions
CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Not listed Phase 1 Interventional

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

NCT04660929
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 28, 2026, 9:36 AM EDT
Recruiting Phase 3 Interventional

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions
AP301, AP301 Low Dose
Drug
Lead sponsor
Alebund Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Vagus Nerve Stimulation for Treating Adults With Severe Fibromyalgia

NCT00294281
View directory record Official record
Conditions
Fibromyalgia
Interventions
Vagus Nerve Stimulation (VNS) Therapy
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
21 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 28, 2026, 9:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 28, 2026, 9:36 AM EDT